JP2024516037A5 - - Google Patents
Info
- Publication number
- JP2024516037A5 JP2024516037A5 JP2023567924A JP2023567924A JP2024516037A5 JP 2024516037 A5 JP2024516037 A5 JP 2024516037A5 JP 2023567924 A JP2023567924 A JP 2023567924A JP 2023567924 A JP2023567924 A JP 2023567924A JP 2024516037 A5 JP2024516037 A5 JP 2024516037A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- inhibitor
- patient
- solvate
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163184685P | 2021-05-05 | 2021-05-05 | |
| US63/184,685 | 2021-05-05 | ||
| US202263320997P | 2022-03-17 | 2022-03-17 | |
| US63/320,997 | 2022-03-17 | ||
| PCT/US2022/027696 WO2022235817A1 (en) | 2021-05-05 | 2022-05-04 | Combination therapies comprising shp2 inhibitors and pd-1 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516037A JP2024516037A (ja) | 2024-04-11 |
| JP2024516037A5 true JP2024516037A5 (https=) | 2025-05-14 |
Family
ID=83932910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023567924A Pending JP2024516037A (ja) | 2021-05-05 | 2022-05-04 | Ｓｈｐ２阻害剤とｐｄ－１阻害剤とを含む併用療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12097203B2 (https=) |
| EP (1) | EP4334318A4 (https=) |
| JP (1) | JP2024516037A (https=) |
| AU (1) | AU2022271243A1 (https=) |
| CA (1) | CA3217084A1 (https=) |
| IL (1) | IL308222A (https=) |
| MX (1) | MX2023013064A (https=) |
| WO (1) | WO2022235817A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023012929A (es) * | 2021-05-05 | 2023-11-13 | Huyabio Int Llc | Terapias de combinacion que comprenden inhibidores de shp2 e inhibidores de tirosina cinasa egfr. |
| AU2023385809A1 (en) * | 2022-11-23 | 2025-05-29 | Huyabio International, Llc | Combination therapies comprising KRAS inhibitors and SHP2 inhibitors |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| WO2015107494A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
| US10287266B2 (en) | 2015-06-19 | 2019-05-14 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
| WO2017210134A1 (en) | 2016-05-31 | 2017-12-07 | Board Of Regents, University Of Texas System | Heterocyclic inhibitors of ptpn11 |
| MX388576B (es) | 2016-06-07 | 2025-03-20 | Jacobio Pharmaceuticals Co Ltd | Derivados heterociclicos novedosos utiles como inhibidores de shp2. |
| WO2017216706A1 (en) | 2016-06-14 | 2017-12-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| EP4302834A3 (en) | 2016-07-12 | 2024-07-17 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| CA3048340A1 (en) | 2017-01-10 | 2018-07-19 | Novartis Ag | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
| EA202190196A1 (ru) | 2017-03-23 | 2021-08-31 | Джакобио Фармасьютикалс Ко., Лтд. | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 |
| CA3074690A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| TW201930292A (zh) | 2017-10-12 | 2019-08-01 | 美商銳新醫藥公司 | 作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物 |
| US11110171B2 (en) * | 2017-12-21 | 2021-09-07 | New York University | PD-1 related cancer therapy |
| WO2019152454A1 (en) | 2018-01-30 | 2019-08-08 | Research Development Foundation | Shp2 inhibitors and methods of use thereof |
| RU2020133727A (ru) | 2018-03-21 | 2022-04-21 | Сучжоу Пухе Биофарма Ко., Лтд. | Ингибиторы shp2 и их применение |
| MX2020010719A (es) | 2018-04-10 | 2020-11-06 | Revolution Medicines Inc | Composiciones de inhibidores de shp2, metodos para tratar el cancer y metodos para identificar a un sujeto con mutaciones en shp2. |
| JP2022508651A (ja) * | 2018-10-08 | 2022-01-19 | レヴォリューション・メディスンズ，インコーポレイテッド | 癌を処置するためのｓｈｐ２阻害剤組成物および方法 |
| MX2021009562A (es) | 2019-02-12 | 2021-09-08 | Novartis Ag | Combinacion farmaceutica que comprende tno155 y un inhibidor de pd-1. |
| CN111647000B (zh) * | 2019-03-04 | 2021-10-12 | 勤浩医药（苏州）有限公司 | 吡嗪类衍生物及其在抑制shp2中的应用 |
| CN114502165A (zh) | 2019-09-23 | 2022-05-13 | 苏州浦合医药科技有限公司 | Shp2抑制剂及其用途 |
-
2022
- 2022-05-04 IL IL308222A patent/IL308222A/en unknown
- 2022-05-04 US US17/736,879 patent/US12097203B2/en active Active
- 2022-05-04 CA CA3217084A patent/CA3217084A1/en active Pending
- 2022-05-04 JP JP2023567924A patent/JP2024516037A/ja active Pending
- 2022-05-04 EP EP22799520.6A patent/EP4334318A4/en not_active Withdrawn
- 2022-05-04 AU AU2022271243A patent/AU2022271243A1/en active Pending
- 2022-05-04 WO PCT/US2022/027696 patent/WO2022235817A1/en not_active Ceased
- 2022-05-04 MX MX2023013064A patent/MX2023013064A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024516997A5 (https=) | ||
| AU2009279771B2 (en) | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine | |
| JP2019518741A5 (https=) | ||
| US11976064B2 (en) | Toll-like receptor agonists | |
| JP2024059647A5 (https=) | ||
| JP2019501204A5 (https=) | ||
| JP2024516037A5 (https=) | ||
| JP2016503414A5 (https=) | ||
| JP2018504418A5 (https=) | ||
| JP2020536971A5 (https=) | ||
| JP2020506945A (ja) | がんの治療のための方法、組成物及びキット | |
| JPWO2020032105A5 (https=) | ||
| KR102936318B1 (ko) | 소세포폐암의 병용 치료용 퀴놀린 유도체 | |
| JP7154634B2 (ja) | 腫瘍免疫賦活剤 | |
| JP2006518726A5 (https=) | ||
| JP2024516998A5 (https=) | ||
| JP2022550040A5 (https=) | ||
| JP2021515016A5 (https=) | ||
| JPWO2023204259A5 (https=) | ||
| CN110891944A (zh) | 用于治疗癌症的化合物、组合物及其用途 | |
| TW202604574A (zh) | 抗體藥物偶聯物在預防或治療疾病中的應用 | |
| HK40113079A (en) | Antineoplastic combinations of neratinib and capecitabine | |
| WO2025241959A1 (zh) | 抗体药物偶联物在预防或治疗疾病中的应用 | |
| JP2026506975A (ja) | 薬物コンジュゲートの腫瘍疾患治療における使用および方法 | |
| OA20485A (en) | IMIDAZO[4,5-C]pyridine derivatives as tolllike receptor agonsits |